Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
$2.39
+5.5%
$2.54
$1.78
$10.14
$49.82M0.7266,840 shs73,586 shs
Alector, Inc. stock logo
ALEC
Alector
$1.48
-1.7%
$1.35
$0.87
$6.78
$147.49M0.74839,031 shs233,289 shs
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$8.01
-2.9%
$7.79
$5.01
$18.71
$47.74M0.18118,318 shs18,894 shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$16.80
0.0%
$15.33
$12.72
$34.47
$2.87B0.631.22 million shs511,903 shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$33.24
-0.1%
$33.32
$27.66
$121.06
$4.29B1.191.48 million shs474,884 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
0.00%+2.80%-15.72%-34.30%-65.38%
Alector, Inc. stock logo
ALEC
Alector
0.00%-0.34%-1.01%+46.04%-66.40%
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
0.00%+0.63%-13.22%+39.79%-3.26%
Immunovant, Inc. stock logo
IMVT
Immunovant
0.00%+4.37%+0.20%+16.78%-37.50%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
0.00%+2.01%-10.15%+2.23%-57.28%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
4.0838 of 5 stars
3.43.00.04.80.02.50.6
Alector, Inc. stock logo
ALEC
Alector
3.8331 of 5 stars
3.13.00.04.51.12.50.0
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
4.1076 of 5 stars
3.33.00.04.70.62.50.6
Immunovant, Inc. stock logo
IMVT
Immunovant
1.3965 of 5 stars
3.52.00.00.00.01.70.0
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
1.7706 of 5 stars
3.61.00.00.02.11.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
2.80
Moderate Buy$23.80897.90% Upside
Alector, Inc. stock logo
ALEC
Alector
2.14
Hold$4.00171.19% Upside
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
2.57
Moderate Buy$17.75121.60% Upside
Immunovant, Inc. stock logo
IMVT
Immunovant
2.90
Moderate Buy$38.33128.12% Upside
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.10
Buy$136.50310.71% Upside

Current Analyst Ratings Breakdown

Latest ATRA, PCVX, ALEC, IMVT, and ADVM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$16.00 ➝ $12.00
5/15/2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$5.00 ➝ $4.00
5/15/2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$33.00 ➝ $33.00
5/15/2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
5/9/2025
Alector, Inc. stock logo
ALEC
Alector
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $10.00
4/22/2025
Immunovant, Inc. stock logo
IMVT
Immunovant
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$38.00 ➝ $17.00
4/22/2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight
4/17/2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$40.00 ➝ $33.00
4/16/2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$10.00 ➝ $5.00
4/16/2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
4/8/2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
$1M49.82N/AN/A$3.40 per share0.70
Alector, Inc. stock logo
ALEC
Alector
$100.56M1.47N/AN/A$1.29 per share1.14
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$128.94M0.37N/AN/A($16.89) per share-0.47
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/A$4.16 per shareN/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/A$26.52 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
-$130.93M-$6.40N/AN/AN/AN/A-130.53%-66.31%8/11/2025 (Estimated)
Alector, Inc. stock logo
ALEC
Alector
-$119.05M-$1.26N/AN/AN/A-139.74%-100.58%-25.15%8/6/2025 (Estimated)
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-$85.40M-$3.72N/AN/AN/A-7.83%N/A-14.51%8/11/2025 (Estimated)
Immunovant, Inc. stock logo
IMVT
Immunovant
-$413.84M-$2.74N/AN/AN/AN/A-80.60%-71.89%8/5/2025 (Estimated)
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$463.93M-$3.99N/AN/AN/AN/A-17.12%-16.26%8/5/2025 (Estimated)

Latest ATRA, PCVX, ALEC, IMVT, and ADVM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/29/2025Q4 2025
Immunovant, Inc. stock logo
IMVT
Immunovant
-$0.72-$0.64+$0.08-$0.64N/A$0.16 million
5/15/2025Q1 2025
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-$3.07$3.50+$6.57$3.50$4.30 million$98.10 million
5/14/2025Q1 2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$1.02-$1.04-$0.02-$1.04N/AN/A
4/15/2025Q4 2024
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
-$1.34-$1.96-$0.62-$1.96N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
N/AN/AN/AN/AN/A
Alector, Inc. stock logo
ALEC
Alector
N/AN/AN/AN/AN/A
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
N/AN/AN/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/AN/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
N/A
3.57
3.57
Alector, Inc. stock logo
ALEC
Alector
0.10
3.34
3.34
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
N/A
0.57
0.57
Immunovant, Inc. stock logo
IMVT
Immunovant
N/A
11.16
11.16
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/A
17.70
17.70

Institutional Ownership

CompanyInstitutional Ownership
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
48.17%
Alector, Inc. stock logo
ALEC
Alector
85.83%
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
70.90%
Immunovant, Inc. stock logo
IMVT
Immunovant
47.08%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
96.78%

Insider Ownership

CompanyInsider Ownership
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
6.00%
Alector, Inc. stock logo
ALEC
Alector
9.10%
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
4.00%
Immunovant, Inc. stock logo
IMVT
Immunovant
5.90%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
19020.89 million19.64 millionOptionable
Alector, Inc. stock logo
ALEC
Alector
27099.99 million90.89 millionOptionable
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
3305.96 million5.72 millionOptionable
Immunovant, Inc. stock logo
IMVT
Immunovant
120170.92 million160.84 millionOptionable
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
160129.00 million125.01 millionOptionable

Recent News About These Companies

Vaxcyte: Sentiment Is Pushing The Shares Down
Vaxcyte appoints new independent director
TD Cowen Keeps Their Buy Rating on Vaxcyte (PCVX)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adverum Biotechnologies stock logo

Adverum Biotechnologies NASDAQ:ADVM

$2.38 +0.13 (+5.53%)
Closing price 07/3/2025 02:21 PM Eastern
Extended Trading
$2.33 -0.05 (-2.31%)
As of 07/3/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Alector stock logo

Alector NASDAQ:ALEC

$1.48 -0.03 (-1.67%)
Closing price 07/3/2025 03:51 PM Eastern
Extended Trading
$1.48 0.00 (0.00%)
As of 07/3/2025 04:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Atara Biotherapeutics stock logo

Atara Biotherapeutics NASDAQ:ATRA

$8.01 -0.24 (-2.91%)
Closing price 07/3/2025 03:37 PM Eastern
Extended Trading
$8.32 +0.31 (+3.86%)
As of 07/3/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Immunovant stock logo

Immunovant NASDAQ:IMVT

$16.80 -0.01 (-0.04%)
Closing price 07/3/2025 02:41 PM Eastern
Extended Trading
$16.80 +0.00 (+0.01%)
As of 07/3/2025 04:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Vaxcyte stock logo

Vaxcyte NASDAQ:PCVX

$33.24 -0.04 (-0.11%)
As of 07/3/2025 03:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.